Adiponectin: a therapeutic target in the antiphospholipid syndrome?

Bećarevic, Mirjana; Nikolic, Bozana; Ignjatović, Svetlana

doi:10.1007/s00296-019-04349-x

Cited by 3 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several molecules might serve as adiponectin replacement agents by exerting their biological effect either by activating the adiponectin signaling pathway or by upregulating the expression of adiponectin itself [ 120 ]. PPARγ agonists, which mainly include efatutazone [ 62 ] and thiazolidinediones (TZDs) and also called glitazones, which are a class of synthetic small molecules and anti-diabetic drugs that enclose rosiglitazone, troglitazone, and pioglitazone [ 121 , 122 , 123 , 124 , 125 , 126 ], are the main and most studied molecules that could have a potential therapeutic effect by inducing the expression and secretion of adiponectin.…”

Section: Reactivation Of Adiponectin Pathways In Breast Cancer Modelsmentioning

confidence: 99%

Targeting Adiponectin in Breast Cancer

et al. 2022

View full text Add to dashboard Cite

Obesity and breast cancer are two major health issues that could be categorized as sincere threats to human health. In the last few decades, the relationship between obesity and cancer has been well established and extensively investigated. There is strong evidence that overweight and obesity increase the risk of postmenopausal breast cancer, and adipokines are the central players in this relationship. Produced and secreted predominantly by white adipose tissue, adiponectin is a bioactive molecule that exhibits numerous protective effects and is considered the guardian angel of adipokine. In the obesity–cancer relationship, more and more evidence shows that adiponectin may prevent and protect individuals from developing breast cancer. Recently, several updates have been published on the implication of adiponectin in regulating tumor development, progression, and metastases. In this review, we provide an updated overview of the metabolic signaling linking adiponectin and breast cancer in all its stages. On the other hand, we critically summarize all the available promising candidates that may reactivate these pathways mainly by targeting adiponectin receptors. These molecules could be synthetic small molecules or plant-based proteins. Interestingly, the advances in genomics have made it possible to create peptide sequences that could specifically replace human adiponectin, activate its receptor, and mimic its function. Thus, the obvious anti-cancer activity of adiponectin on breast cancer should be better exploited, and adiponectin must be regarded as a serious biomarker that should be targeted in order to confront this threatening disease.

show abstract

Section: Reactivation Of Adiponectin Pathways In Breast Cancer Modelsmentioning

confidence: 99%

Targeting Adiponectin in Breast Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…APS is characterized by recurrent thrombosis associated with the synthesis of such antibodies as: AFA, to AKA, β2-HP-I, belongs to acquired thrombophilias and is a manifestation of autoimmune thrombosis. The prevalence of APS in the general population ranges from 1-5%, and according to some estimates, the frequency of APS is about 5 new cases per 100,000 people per year with a prevalence of about 40-50 cases per 100,000 people [1,2,3].…”

mentioning

confidence: 99%

Study of immunological activity and hemostasiological features in rats with experimental antiphospholipid syndrome

Savytskyi

2022

J Educ Health Sport

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is a systemic autoimmune disease, which is characterized by thrombotic or obstetric events characterized by the presence in the blood of patients of a high titer of antibodies to natively charged membrane phospholipids, as well as to glycoproteins associated with them. The role of etiological factors, triggering mechanisms, especially at the initial stages of APS formation, is not clearly defined that’s why the aim of our work was to study of immunological activity and hemostasiological features in rats with experimental antiphospholipid syndrome. In animals with simulated APS, a positive microprecipitation reaction with cardiolipin antigen was observed, which indicated the development of APS. The development of hypercoagulation due to both the vascular and platelet and coagulation links of the hemostasis system was also noted. Established changes in hemocoagulation indicators in APS occur due to the interaction of blood clotting factors with APA.

show abstract